TITLE

Heart implant recall shakes patients

AUTHOR(S)
Webster, Richard A.
PUB. DATE
July 2005
SOURCE
New Orleans CityBusiness (1994 to 2008);7/11/2005, Vol. 25 Issue 53, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the increasing telephone calls from terrified patients following the recall of cardiac defibrillators by cardiovascular product manufacturer Guidant Corp. in the U.S. Discovery of flaw that could prevent the devices from delivering a life-saving shock to the heart; Payment of patient costs involved in the recall; Risk of patient who have a defibrillator but have never suffered a cardiac arrest.
ACCESSION #
17678922

 

Related Articles

  • Stuck with the check? Becker, Cinda // Modern Healthcare;6/27/2005, Vol. 35 Issue 26, p20 

    Reports on the recall of implantable cardiac defibrillators (ICD) by Guidant Corp. in the U.S. in June 2005. Cost of the device; Background on ICD; Problems encountered by patients at Indiana Heart Hospital in Indianapolis with the device.

  • Boston Scientific ICD recalls.  // Materials Management in Health Care;Aug2006, Vol. 15 Issue 8, p8 

    The article reports that Massachusetts-based Boston Scientific Corp. is continuing the recall of certain models of cardiac resynchronization pacemakers and implantable cardioverter defibrillators produced by Guidant, which was acquired by Boston. The United States Food and Drug Administration...

  • Boston Sci sees up-tick in Guidant ICD-related suits.  // Medical Technology & Devices Week;3/12/2007, Vol. 5 Issue 11, p3 

    The article focuses on reports from Boston Scientific about the increase in the number of lawsuits against Guidant's heart rhythm devices. The company now faces more than 1,100 individual and 75 class action lawsuits over recalls and safety warnings issued in 2005 and 2006 involving Guidant's...

  • Fatalities and failures prompt recall of cardiac defibrillators.  // Consumer Reports;Sep2005, Vol. 70 Issue 9, p11 

    Reports that two deaths and dozens of product failures have led to a worldwide recall of tens of thousands of cardiac defibrillators designed by the Guidant Corp., which have been implanted in patients susceptible to dangerous abnormal heart rhythms. Review of how the devices are designed to...

  • Nearly one-fourth of ICD implants failed to meet implantation criteria. Ellis, Brian // Cardiology Today;Feb2011, Vol. 14 Issue 2, p1 

    The article discusses a study which found out that non-evidence based implantation of an implantable cardioverter defibrillator (ICD) could increase the risk of in-hospital death and post-procedural complications.

  • Update on implantable cardioverter-defibrillators. Sadovsky, Richard // American Family Physician;2/15/1997, Vol. 55 Issue 3, p936 

    Focuses on a study by A. Raviele, published in a 1996 edition of the `American Journal of Cardiology,' which highlighted the implantation of cardioverter-defibrillators in the treatment of survivors of cardiac arrest who failed to respond adequately to pharmacologic and surgical interventions....

  • Home monitoring reduces inappropriate ICD shocks by 52%.  // British Journal of Hospital Medicine (17508460);Feb2013, Vol. 74 Issue 2, p70 

    The article reports Biotronik, has published the clinical results of the trial Effectiveness and Cost of ICD Follow-Up Schedule with Telecardiology (ECOST), which states that home monitoring reduces inappropriate implantable cardioverter-defibrillators (ICD) shocks by 52 percent.

  • Cardiac Devices May Benefit Healthier Heart Patients.  // Heart Advisor;Oct2014, Vol. 17 Issue 10, p9 

    The article reports on a study which suggests that patients with less severe heart impairment are more likely to have better survival times with implantable cardioverter defibrillators (ICDs) than their counterparts.

  • FDA delays hinder Guidant. Jefferson // Indianapolis Business Journal;12/13/99, Vol. 20 Issue 40, p1A 

    Focuses on developments related to Indianapolis, Indiana-based medical apparatus vendor Guidant Corp. as of December 13, 1999. Drop in the price of the company's stock caused by the delay in the United States Food and Drug Administration's (FDA) approval of the company's TriStar coronary stent;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics